American healthcare now costs more than $5 trillion a year — nearly one-fifth of the entire U.S. economy.

But where does all that money actually come from? And where does it go?

In this first episode of a new Reimagine Healthcare series, Noah Volz breaks down the money machine behind American healthcare in plain English. Households, employers, the federal government, and state governments all help finance the system. The money then flows through hospitals, physician groups, drug companies, insurers, administrative layers, and a web of billing rules that most people never fully see.

The result is a system that is not just expensive, but structurally expensive.

This episode explains why healthcare costs keep rising even when patients, employers, doctors, hospitals, and governments all feel under pressure. It looks at the role of employer-sponsored insurance, Medicare and Medicaid, hospital consolidation, prescription drugs, administrative complexity, chronic disease, and weak price signals.

And because this is Reimagine Healthcare, we bring the national story home to Southern Oregon.

In Medford, Ashland, Grants Pass, and across the Rogue Valley, healthcare costs shape household budgets, local business decisions, school district finances, county budgets, hiring, wages, and access to care.

In this episode, you’ll learn:

• Where America’s healthcare money comes from
• Where the money goes
• Why employer-sponsored insurance became so dominant
• Why healthcare does not behave like a normal market
• How administrative complexity drives cost
• Why chronic disease makes the system harder to finance
• Why Southern Oregon feels national healthcare inflation so directly
• What families, employers, clinicians, and civic leaders can do with this information

The point is not to give you one magic reform. It is to help you see the machine clearly enough to make better decisions.

Subscribe at reimagine-healthcare.org for more plain-English healthcare analysis rooted in Southern Oregon.

This podcast is for educational purposes only and is not medical advice.

What would it take to prevent Alzheimer’s before it becomes obvious?

In this third and final episode of our series on women’s brain health and Alzheimer’s disease, Noah Volz looks at the system Southern Oregon would need to build if it took prevention seriously.

The numbers are sobering. The lifetime cost of dementia care is estimated at more than $400,000 per person, and much of that burden falls on families through unpaid caregiving and out-of-pocket costs. Oregon already has tens of thousands of people living with Alzheimer’s, and the impact will continue to grow across families, employers, Medicaid, and local healthcare systems.

But this episode is not just about the crisis. It is about what Southern Oregon could build next.

You’ll hear five concrete asks for the region:

• A dedicated Alzheimer’s prevention clinic
• Menopause-literate primary care
• Payment models that reward prevention
• Local readiness for emerging research like the CARE Initiative
• A Southern Oregon Brain Health Coalition

The core question is simple: will Southern Oregon keep waiting until cognitive decline is obvious, or will we build a system that catches risk earlier, supports women in midlife, and makes prevention practical?

This episode is for women in midlife, primary care clinicians, healthcare administrators, payers, policymakers, and anyone who cares about the future of brain health in Southern Oregon.

Subscribe at reimagine-healthcare.org for future reporting, local events, and next steps as this conversation turns into regional action.

This podcast is for educational purposes only and is not medical advice.

Carol is 54, hikes the Siskiyous on weekends, and has been forgetting words mid-sentence for two years. Her doctor ran the standard tests, found nothing, and told her it's just part of getting older.

Her doctor is probably wrong.

This is the first episode in a three-part series on Alzheimer's disease in women — drawing on the research of Dr. Lisa Mosconi, director of the Women's Brain Initiative at Weill Cornell Medicine, and grounded in what Southern Oregon currently has, and critically lacks, for women navigating this risk right now.

In This Episode, You'll Learn:

• Why the standard explanation for women's higher Alzheimer's rate — that women live longer — falls apart the moment you press on it, and what the brain imaging data points to instead
• Why Alzheimer's is a midlife disease that shows up in old age — and why the 20-year preclinical window means Carol's doctor's cognitive test was measuring the wrong moment entirely
• What estrogen is actually doing in the brain, why menopause is fundamentally a brain event before it's anything else, and what Dr. Mosconi's imaging studies found happening to women's brains before their final menstrual period
• The APOE4 number most women with genetic testing have been given — and why that number may be dramatically underestimated because it was calculated on populations that combined men and women
• What Southern Oregon actually has for women like Carol: Asante's neurology department, select gynecology practices willing to discuss hormone therapy, and one nationally recognized integrative practitioner in Ashland — along with an honest account of who can actually access that care
• Why the standard cognitive tests used in most Southern Oregon primary care offices are designed to detect moderate dementia, not prevent it — and what that means for thousands of women currently in the highest-risk window

The uncomfortable truth: Carol's doctor isn't negligent. The system is using the tools it was built with. Those tools weren't designed for what Carol actually needs — and by the time they are, the 20-year window for prevention will have closed.

This episode is for you if:

• You're a woman in your 40s or 50s noticing cognitive changes you can't explain
• You've had APOE4 genetic testing and want to understand what that result actually means for women specifically
• You have a family history of Alzheimer's and want to know what questions to bring to your next appointment
• You believe Southern Oregon can do better for the thousands of women currently in this risk window

Subscribe to the newsletter at reimagine-healthcare.org for episode updates and a list of questions to bring to your next doctor's appointment.

Kathleen's labs had been normal for three years. She was on medication. She was still disappearing.

This final episode of the thyroid series follows Kathleen through the six months after her extended labs changed everything — and makes a direct case for what Southern Oregon's healthcare infrastructure needs to build so that her story becomes the rule, not a lucky accident.

What produced Kathleen's recovery wasn't a system. It was a series of accidents in her favor: the right book, a physician willing to listen, a phone call that took ten minutes and was worth three years. For every patient who gets those accidents, dozens don't.

Here's what the episode covers:

• Why Kathleen was already on combination therapy and still not getting better — and what the pharmacokinetics of oral T3 reveal about how delivery method matters as much as what you're taking
• The honest evidence on levothyroxine monotherapy: why it works for 80 to 85 percent of patients, and what a mortality dataset of over a million people shows about the meaningful minority it doesn't serve
• The 30 percent all-cause mortality reduction seen in patients on combination T4 and T3 therapy — and why that signal hasn't produced the clinical response it would in any other area of medicine
• Why the liver of a patient on levothyroxine with normal TSH may still be relatively hypothyroid — and what that explains about why statins are the most commonly co-prescribed drug alongside thyroid medication
• Desiccated thyroid extract versus synthetic combination therapy: what the blinded crossover trials actually show, what the legitimate concerns are, and where the ideology on both sides parts ways with the evidence
• What compounded controlled-release T3 claims versus what the only published pharmacokinetic study of those products actually found
• The functional medicine interventions with genuine evidence behind them — and the ones that go well beyond it
• What Kathleen's six-month lab results looked like: free T3, reverse T3 ratio, LDL cholesterol, anti-TPO antibodies — and what changed in her life when the numbers finally moved
• Five specific infrastructure changes Southern Oregon could build now: a shared diagnostic protocol, care coordination pathways between conventional and functional providers, insurance advocacy for comprehensive testing, regional CME, and a prospective outcomes registry

The uncomfortable truth: Good medicine happens when the patient's lived experience is treated as data and the physician's training is a starting point for inquiry, not a closed file. For Kathleen, that combination arrived three years late. The science, the practitioners, and the patients are already here. What's missing is the connective tissue that turns motivated individuals into a system that reliably serves everyone who needs it.

This episode is for you if:

• You've completed the series and want to understand what treatment options the evidence actually supports
• You're a Southern Oregon provider looking for a roadmap grounded in peer-reviewed research
• You believe the parallel silo between conventional and functional medicine is costing patients — and you want to see what closing it looks like in practice

Subscribe to the newsletter at reimagine-healthcare.org for updates on thyroid care in Southern Oregon and new episodes.

Your labs came back normal. You're still exhausted. And here's the part nobody tells you: the test your doctor used to make that call may not have been accurate enough to know.

Episode two of the thyroid series gets specific. After last week's episode on why the standard TSH-and-T4 framework misses most of the biological story, this episode is about the labs — what should actually be measured, why the standard panel leaves critical questions unanswered, and why even when the right test is ordered, the method used to run it may be producing results that look precise but aren't.

This is what Kathleen's doctors were missing for three years. And it's what most hypothyroid patients in Southern Oregon have never been told to ask for.

In this episode, you'll discover:

• Why TSH has three fundamental limitations that make it dangerous to use as your only guide — and what the research says about the true upper limit of a healthy TSH range
• Why free T4 tells you the pantry is stocked but nothing about whether anyone is being fed
• Why free T3 — the only hormone that actually drives energy, cognition, and metabolism — is still routinely excluded from standard thyroid panels
• The measurement method problem: why the immunoassay most labs use for free T3 produces falsely normal results nearly half the time in the range that matters most, and why LC-MS/MS mass spectrometry is the only reliable alternative
• What reverse T3 is, why an elevated level means your body is deliberately throttling its own thyroid activity, and why this never shows up on a standard panel
• Why ferritin, selenium, vitamin D, and zinc are not optional add-ons — they're the raw materials the conversion enzymes can't work without
• The specific labs Kathleen's extended panel revealed that three years of standard testing had completely missed — and why each result made immediate clinical sense once someone finally looked

The uncomfortable truth: the path of least resistance for physicians and health systems is the minimal panel. Insurance coverage is inconsistent. Appointment time is short. Deviating from defaults takes deliberate effort. The patient pays the price in years of undertreated symptoms and a diagnosis that keeps getting deferred.

This episode is for you if:

• You're on thyroid medication but still experiencing fatigue, brain fog, or weight gain you can't explain
• You've been told your labs are normal more than once and you're starting to wonder what normal actually means
• You want a specific, printable checklist of what to ask for at your next appointment
• You're a Southern Oregon patient navigating Asante, Providence Medford, Quest, or LabCorp and want to know exactly how to request the right methodology

Subscribe to the newsletter at reimagine-healthcare.org — including a downloadable checklist of every lab discussed in this episode, formatted to take directly to your doctor.

You've been told your thyroid labs are normal. You're on medication. And you're still exhausted, still foggy, still canceling the life you used to have. Nobody can explain why.

For somewhere between ten and fifteen percent of people being treated for hypothyroidism right now, that is exactly what's happening. This episode is the first in a three-part series investigating the gap between what the science actually says about how the thyroid works and what most patients in Southern Oregon are receiving as care. That gap is real, well-documented, and affecting a significant number of people in this region.

In This Episode, You'll Learn:

• Why TSH — the number your doctor uses to manage your thyroid — measures the pituitary's satisfaction, not your tissues' actual hormone supply
• How the active thyroid hormone that drives energy, cognition, and metabolism is produced largely outside the bloodstream, in places a standard blood test can't see
• Why the same T4 medication prescribed to nearly every hypothyroid patient is biologically inactive until converted — and why that conversion often fails under chronic stress or inflammation
• What Hashimoto's thyroiditis is actually doing to the immune system beyond destroying the thyroid — and why replacing the hormone doesn't address the root problem
• Why selenium and vitamin D have clinical trial evidence behind them for slowing autoimmune thyroid destruction, and why standard care typically doesn't discuss this
• The specific combination of symptoms and TSH levels that should prompt you to ask for a more complete panel — before you've spent years undertreated
• Why Southern Oregon's endocrinologist shortage and the silo between conventional and functional medicine practitioners is leaving patients like Kathleen doing the coordination work the system should be doing for them

The uncomfortable truth: This isn't fringe science. It's the published research of leading thyroid physiologists, documented in peer-reviewed journals. The gap between that science and standard clinical practice isn't academic. For Kathleen — 46 years old, running a business outside Medford, slowly disappearing from her own life — it was three years.

This episode is for you if:

• You've been told your labs are normal but you still feel terrible
• You're on thyroid medication and haven't experienced the improvement you expected
• You have a family history of autoimmune disease or are entering perimenopause
• You're a Southern Oregon patient navigating long specialist wait times and want to know what questions to ask
• You're a provider or employer who wants to understand why thyroid disease is being systematically undermanaged in this region

Subscribe to the newsletter at reimagine-healthcare.org — including a checklist you can take to your next appointment and information about Jackson County providers who do comprehensive thyroid testing.

What if the solution to Southern Oregon’s healthcare affordability crisis already existed—and was working in markets just like ours?

In this final episode of the series, we break down the most promising strategy for reducing healthcare costs in Southern Oregon: employer purchasing alliances.

Across the country, groups of employers are joining forces to negotiate better healthcare pricing, implement direct primary care, eliminate pharmacy middlemen, and redesign benefits around value instead of dysfunction.

The results? Lower premiums. Lower deductibles. Lower out-of-pocket costs. Better care.

In This Episode, You’ll Learn:

• How employer purchasing alliances create leverage small businesses can’t achieve alone • Why markets like Wisconsin, Montana, Idaho, and Colorado have reduced costs 13–17% using this model • How Direct Primary Care improves outcomes while lowering overall spending • Why reference-based pricing can cut surgical costs by 25–40% • How transparent PBM carve-outs reduce prescription spending • What it would take to build a successful employer alliance in Southern Oregon • How these reforms could save a typical local family over $5,000 per year

The bottom line: Southern Oregon’s healthcare crisis is not unsolvable. The economics are clear. The models already exist.

What remains is coordination—and the willingness of employers, policymakers, providers, and community leaders to act.

If you care about healthcare reform, employer-sponsored insurance, direct primary care, or the future of Southern Oregon’s economy, this episode is essential listening.

Why does the same family pay thousands more for healthcare in Southern Oregon than they would in Portland, Eugene, or Boise?

In this episode, we expose the hidden market forces driving Southern Oregon’s healthcare affordability crisis—and why the problem goes far beyond deductibles and insurance design.

Because this isn’t just bad luck. It’s not overuse. And it’s not because patients are making poor decisions.

It’s a structural market failure.

From insurance carrier consolidation and hospital market power to pharmacy benefit manager dysfunction and the “small employer trap,” we break down the real reasons Southern Oregon families and businesses pay dramatically more for healthcare than comparable regions.

In This Episode, You’ll Learn:

• Why Southern Oregon healthcare costs are 21–37% higher than comparable markets • How carrier consolidation limits employer negotiating power • Why hospital market concentration drives prices up without improving outcomes • How pharmacy benefit managers quietly extract millions from the region • Why small employers are structurally disadvantaged in healthcare negotiations • Which Oregon policies have failed—and what gaps remain • Why individual action can’t solve a structural market problem

The bottom line: Southern Oregon’s healthcare crisis is not just an insurance problem. It’s a market design problem.

And until we address the structural forces behind rising costs, families will keep paying more, employers will keep struggling, and the region will continue to lose people and economic momentum.

If you care about healthcare reform, employer-sponsored insurance, market consolidation, or the future of Southern Oregon’s economy—this episode is essential listening.